Your browser doesn't support javascript.
The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutation.
Ginex, Tiziana; Marco-Marín, Clara; Wieczór, Milosz; Mata, Carlos P; Krieger, James; Ruiz-Rodriguez, Paula; López-Redondo, Maria Luisa; Francés-Gómez, Clara; Melero, Roberto; Sánchez-Sorzano, Carlos Óscar; Martínez, Marta; Gougeard, Nadine; Forcada-Nadal, Alicia; Zamora-Caballero, Sara; Gozalbo-Rovira, Roberto; Sanz-Frasquet, Carla; Arranz, Rocío; Bravo, Jeronimo; Rubio, Vicente; Marina, Alberto; Geller, Ron; Comas, Iñaki; Gil, Carmen; Coscolla, Mireia; Orozco, Modesto; Llácer, José Luis; Carazo, Jose-Maria.
  • Ginex T; Centro de Investigaciones Biológicas Margarita Salas (CIB-CSIC), Madrid, Spain.
  • Marco-Marín C; Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain.
  • Wieczór M; Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Madrid, Spain.
  • Mata CP; Molecular Modeling and Bioinformatics, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Krieger J; Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.
  • Ruiz-Rodriguez P; Centro Nacional de Microbiología (CNM-ISCIII), Instituto de Salud Carlos III, Madrid, Spain.
  • López-Redondo ML; Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.
  • Francés-Gómez C; I2SysBio, University of Valencia-CSIC, FISABIO Joint Research Unit Infection and Public Health, Valencia, Spain.
  • Melero R; Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain.
  • Sánchez-Sorzano CÓ; I2SysBio, University of Valencia-CSIC, FISABIO Joint Research Unit Infection and Public Health, Valencia, Spain.
  • Martínez M; Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.
  • Gougeard N; Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.
  • Forcada-Nadal A; Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.
  • Zamora-Caballero S; Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain.
  • Gozalbo-Rovira R; Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Madrid, Spain.
  • Sanz-Frasquet C; Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain.
  • Arranz R; Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Madrid, Spain.
  • Bravo J; Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain.
  • Rubio V; Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain.
  • Marina A; Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain.
  • Geller R; Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain.
  • Comas I; Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain.
  • Gil C; Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Madrid, Spain.
  • Coscolla M; Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain.
  • Orozco M; Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Madrid, Spain.
  • Carazo JM; I2SysBio, University of Valencia-CSIC, FISABIO Joint Research Unit Infection and Public Health, Valencia, Spain.
PLoS Pathog ; 18(7): e1010631, 2022 07.
Article in English | MEDLINE | ID: covidwho-1933392
ABSTRACT
The SA222V point mutation, within the G clade, was characteristic of the 20E (EU1) SARS-CoV-2 variant identified in Spain in early summer 2020. This mutation has since reappeared in the Delta subvariant AY.4.2, raising questions about its specific effect on viral infection. We report combined serological, functional, structural and computational studies characterizing the impact of this mutation. Our results reveal that SA222V promotes an increased RBD opening and slightly increases ACE2 binding as compared to the parent SD614G clade. Finally, SA222V does not reduce sera neutralization capacity, suggesting it does not affect vaccine effectiveness.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: PLoS Pathog Year: 2022 Document Type: Article Affiliation country: Journal.ppat.1010631

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: PLoS Pathog Year: 2022 Document Type: Article Affiliation country: Journal.ppat.1010631